S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
The "King Of Quants" sees 10X potential... (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
The gold catalyst we’ve waited for (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
The gold catalyst we’ve waited for (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
The "King Of Quants" sees 10X potential... (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
The gold catalyst we’ve waited for (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
The gold catalyst we’ve waited for (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
The "King Of Quants" sees 10X potential... (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
The gold catalyst we’ve waited for (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
The gold catalyst we’ve waited for (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
The "King Of Quants" sees 10X potential... (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
The gold catalyst we’ve waited for (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
The gold catalyst we’ve waited for (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
NASDAQ:MESO

Mesoblast - MESO Stock Forecast, Price & News

$3.18
+0.03 (+0.95%)
(As of 03/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.17
$3.23
50-Day Range
$3.03
$4.18
52-Week Range
$2.14
$4.65
Volume
60,540 shs
Average Volume
185,218 shs
Market Capitalization
$468.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.13

Mesoblast MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
218.4% Upside
$10.13 Price Target
Short Interest
Healthy
0.23% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Mesoblast in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.65) to ($0.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

371st out of 1,009 stocks

Biological Products, Except Diagnostic Industry

66th out of 166 stocks


MESO stock logo

About Mesoblast (NASDAQ:MESO) Stock

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Receive MESO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

MESO Stock News Headlines

A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
Mesoblast Limited's (ASX:MSB) Shift From Loss To Profit
See More Headlines
Receive MESO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter.

MESO Company Calendar

Last Earnings
2/27/2023
Today
3/31/2023
Next Earnings (Estimated)
5/30/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MESO
Previous Symbol
OTCMKTS:MBLTY
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.13
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+218.4%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-91,350,000.00
Net Margins
-1,068.42%
Pretax Margin
-1,071.25%

Debt

Sales & Book Value

Annual Sales
$10.21 million
Book Value
$3.82 per share

Miscellaneous

Free Float
119,708,000
Market Cap
$468.80 million
Optionable
Optionable
Beta
3.31

Key Executives

  • Silviu Itescu
    Chief Executive Officer, MD & Executive Director
  • Dagmar Rosa-Bjorkeson
    Chief Operating Officer
  • Andrew Chaponnel
    Chief Financial Officer & Head-Finance
  • Eric A. Rose
    Executive Director & Chief Medical Officer
  • Michael Schuster
    Head-Pharma Partnering













MESO Stock - Frequently Asked Questions

Should I buy or sell Mesoblast stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MESO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares.
View MESO analyst ratings
or view top-rated stocks.

What is Mesoblast's stock price forecast for 2023?

5 Wall Street analysts have issued 1 year target prices for Mesoblast's shares. Their MESO share price forecasts range from $2.50 to $23.00. On average, they anticipate the company's share price to reach $10.13 in the next twelve months. This suggests a possible upside of 218.4% from the stock's current price.
View analysts price targets for MESO
or view top-rated stocks among Wall Street analysts.

How have MESO shares performed in 2023?

Mesoblast's stock was trading at $2.91 at the start of the year. Since then, MESO stock has increased by 9.3% and is now trading at $3.18.
View the best growth stocks for 2023 here
.

Are investors shorting Mesoblast?

Mesoblast saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 341,000 shares, a drop of 54.2% from the February 28th total of 745,100 shares. Based on an average daily volume of 147,500 shares, the short-interest ratio is presently 2.3 days.
View Mesoblast's Short Interest
.

When is Mesoblast's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 30th 2023.
View our MESO earnings forecast
.

How were Mesoblast's earnings last quarter?

Mesoblast Limited (NASDAQ:MESO) announced its quarterly earnings data on Monday, February, 27th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.02. The company had revenue of $2.13 million for the quarter, compared to analysts' expectations of $1.50 million. Mesoblast had a negative net margin of 1,068.42% and a negative trailing twelve-month return on equity of 16.52%.

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV).

When did Mesoblast IPO?

(MESO) raised $69 million in an IPO on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

Who are Mesoblast's major shareholders?

Mesoblast's stock is owned by a variety of retail and institutional investors. Top institutional investors include M&G Investment Management Ltd. (0.66%), Morgan Stanley (0.13%), Hennion & Walsh Asset Management Inc. (0.12%), Millennium Management LLC (0.08%), Group One Trading L.P. (0.00%) and Susquehanna International Group LLP (0.00%).

How do I buy shares of Mesoblast?

Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $3.18.

How much money does Mesoblast make?

Mesoblast (NASDAQ:MESO) has a market capitalization of $468.80 million and generates $10.21 million in revenue each year. The company earns $-91,350,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The official website for the company is www.mesoblast.com. The company can be reached via phone at (139) 639-6036, via email at schond.greenway@mesoblast.com, or via fax at 61-3-9639-6030.

This page (NASDAQ:MESO) was last updated on 3/31/2023 by MarketBeat.com Staff